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Summary
 
Human immunodeficiency virus-1 (HIV-1) expression in monocyte-derived macrophages (MDM)
infected in vitro is known to be inhibited by lipopolysaccharide (LPS). However, the mecha-
nisms are incompletely understood. We show here that HIV-1 suppression is mediated by sol-
uble factors released by MDM stimulated with physiologically significant concentrations of
LPS. LPS-conditioned supernatants from MDM inhibited HIV-1 replication in both MDM
and T cells. Depletion of C–C chemokines (RANTES, MIP-1
 
a
 
, and MIP-1
 
b
 
) neutralized the
ability of LPS-conditioned supernatants to inhibit HIV-1 replication in MDM. A combination
of recombinant C–C chemokines blocked HIV-1 infection as effectively as LPS. Here, we re-
port an inhibitory effect of C–C chemokines on HIV replication in primary macrophages. Our
results raise the possibility that monocytes may play a dual role in HIV infection: while repre-
senting a reservoir for the virus, they may contribute to the containment of the infection by re-
leasing factors that suppress HIV replication not only in monocytes but also in T lymphocytes.
 
M
 
onocyte/macrophages are key players in the patho-
genesis of HIV-1 infection. Macrophages are major
reservoirs for HIV-1 during all stages of infection (1, 2) and
may be among the first cells to be infected by HIV-1 in pa-
tients (3, 4). Unlike T cells, HIV-infected monocytes show
little or no virus-induced cytopathic effects in vitro (5, 6).
HIV-infected macrophages therefore may persist in tissues
for long periods of time and represent a vector for the spread
of the infection to different tissues both within the patients
and between individuals. In addition to this Trojan horse–
like role, it has been recognized that monocytes may play a
regulatory role during HIV infection by controlling the
pace of disease progression through the release of soluble
products (reviewed in 5, 7, 8).
Monocyte/macrophages are critically involved in the
immune response to bacterial infections. LPS/endotoxin,
the major constituent of the cell wall in gram-negative bac-
teria, has been shown to activate monocyte/macrophages
by interacting with a specific receptor, CD14 (9), a glyco-
sylphosphatidylinositol-linked glycoprotein expressed on the
monocytic lineage at high density and less intensely on neu-
trophils (10, 11). CD14 plays a pivotal role in LPS-induced
monokine release during infections and toxic shock (9, 12).
More recently, LPS/CD14 interactions have been shown
to result in the induction of HIV expression in monocytoid
tumor cell lines (13, 14), but to protect primary macrophages
from productive infection by HIV-1 in vitro (15, 16). Nota-
bly, the concentrations of LPS that affect HIV-1 replication
in vitro can be easily reached in vivo and may thus affect
viral replication in patients with HIV superinfected with
bacteria. The mechanisms underlying the complex effects of
LPS on HIV-1 expression in monocytic cells have not been
elucidated so far.
We have studied the effects of LPS on HIV-1 expression
 
in cultures of monocyte-derived macrophages (MDM)
 
1
 
 and
T cells isolated from normal donors, and infected with dif-
ferent strains of HIV-1. Our results show that LPS-depen-
dent inhibition of HIV infection affected T lymphocytes, as
well as MDM, and involved the release of suppressive fac-
tors, most notably, the C–C chemokines RANTES (regu-
lated upon activation, normal T expressed and secreted),
macrophage inflammatory protein (MIP)-1
 
a
 
, and MIP-1
 
b
 
.
 
1
 
Abbreviations used in this paper:
 
 MDM, monocyte-derived macrophages;
MIP, macrophage inflammatory protein; NSI, nonsyncitium-inducing;
RANTES, regulated upon activation, normal T expressed and secreted;
RT, reverse transcriptase.
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Suppression of HIV-1 Infection by LPS-induced Chemokines
 
Materials and Methods
 
Reagents.
 
PE-conjugated anti-CD14 mAb P9 (anti-Leu-M3,
IgG2b) and an isotype control were purchased from Becton
Dickinson (Mountain View, CA). A neutralizing rat anti–human
IL-10 mAb (J53-19F1, IgG2a) was a gift from Dr. J. Abrams
(DNAX Research Institute, Palo Alto, CA). rTNF-
 
a
 
, recombi-
nant C–C chemokines (RANTES, MIP-1
 
a
 
, and MIP-1
 
b
 
), and
neutralizing goat polyclonal antibodies against IL-1 receptor an-
tagonist (IL-1Ra: neutralizing dose, ND
 
50
 
 
 
5
 
 5–10 
 
m
 
g/ml), MIP-1
 
a
 
(ND
 
50
 
 
 
5
 
 10 
 
m
 
g/ml), MIP-1
 
b
 
 (ND
 
50
 
 
 
5
 
 40 
 
m
 
g/ml), and RANTES
(ND
 
50
 
 
 
5
 
 100–200 
 
m
 
g/ml) were obtained from R&D Systems (Min-
neapolis, MN). The mAbs used in the ELISA assay for soluble
TNF receptor 1, and in the immunofluorescence analysis of mem-
brane TNF-
 
a
 
 expression were provided by Dr. A. Corti (Depart-
ment of Biological and Technological Research, San Raffaele
Scientific Institute). Concentrations of TNF-
 
a
 
, IL-6, MIP-1
 
a
 
,
MIP-1
 
b
 
, and RANTES in culture supernatants were determined
by ELISA (Quantikine, R&D Systems).
LPS from 
 
Salmonella minnesota
 
 and purified goat IgG were pur-
chased from Sigma Chemical Co. (St. Louis, MO). The endo-
toxin content of all cell culture reagents was assessed by the Limu-
lus amebocyte lysate assay (Whittaker Bioproducts, Walkersville,
MD), and was always 
 
,
 
0.125 EU/ml. Polymixin B sulfate was
purchased from Calbiochem Novabiochem (La Jolla, CA).
 
Isolation of MDM and HIV-1 Infection.
 
PBMC were isolated
by Ficoll–HyPaque (Pharmacia, Uppsala, Sweden) density gradi-
ent centrifugation from buffy-coat preparations obtained from
healthy donors. The cells were then resuspended in RPMI-1640
(GIBCO BRL, Gaithersburg, MD) supplemented with 10% AB
 
1
 
serum (Sigma), 20% FCS (Biological Industries, Israel), 2 mM
glutamine, 50 
 
m
 
g/ml streptomycin, and 100 U/ml penicillin, and
cultured at a concentration of 1 
 
3
 
 10
 
6
 
 cells/cm
 
2
 
 for 5 d at 37
 
8
 
C
in 6-well tissue culture plates (Nunc, Roskilde, Denmark), in a 3
ml volume. Non-adherent cells were then removed by extensive
washing with medium. The MDM preparations contained 
 
>
 
90%
CD14
 
1
 
 cells, as assessed by immunofluorescence.
Cells were infected with the monocytotropic HIV-1
 
Ba-L
 
 viral
strain (tissue culture infectious dose
 
50
 
, TCID
 
50
 
: 110/10
 
6
 
 MDM)
grown in primary MDM and never previously passaged in con-
tinuous cell lines, or with HIV-1
 
IIIB
 
 grown in PHA-activated
PBMC (TCID
 
50
 
: 45/10
 
6
 
 MDM). Furthermore, cells were infected
with primary viral isolates (HIV-1
 
5088
 
 and HIV-1
 
181
 
) with the bi-
ological characteristics of non syncitium-inducing (NSI) strains.
For infection, MDM were incubated with the viral strains at a
concentration of 500 pg/ml of p24 Ag in RPMI-1640, 20% FCS,
in a total volume of 2 ml of cell-free viral supernatant. After over-
night incubation, unbound virus was removed by extensive
washing, fresh medium (3 ml) was added, and the cultures were
further incubated at 37
 
8
 
C. Supernatants were harvested every day
for p24 Ag detection and reverse transcriptase (RT) determination.
Culture medium was fully replaced every 3–4 d, without washing.
 
Isolation of Lymphocytes and HIV-1 Infection.
 
Normal peripheral
blood lymphocytes depleted of monocytes by two cycles of ad-
herence to plastic were activated by a 3-d incubation with PHA
(1.5 
 
m
 
g/ml; Sigma). The resulting PHA blasts were collected, re-
suspended at 2.5 
 
3
 
 10
 
6
 
 cells/ml in medium containing 10% FCS,
and supplemented with polybrene (2 mg/ml; Sigma) and IL-2 (10
U/ml: Amersham, Buckinghamshire, UK), and incubated over-
night in the presence of HIV-1
 
Ba-L
 
. Subsequently, free virus was
removed by washing twice in RPMI-1640, and the cells (1.5 
 
3
 
10
 
6
 
/ml) were cultured in 6-well plates in the presence of IL-2.
Culture supernatants were harvested every 3–4 d, and tested for
the presence of HIV-1 p24 Ag by ELISA.
 
Preparation of LPS-conditioned and Monokine-depleted Superna-
tants.
 
LPS-conditioned supernatants were prepared by incubat-
ing cultures of normal uninfected MDM in the presence or absence
of LPS (1 
 
m
 
g/ml). 2 d later, supernatants were harvested, centri-
fuged, and stored at 
 
2
 
20
 
8
 
C until used. To deplete LPS-condi-
tioned supernatants of chemokines (MIP-1
 
a
 
, MIP-1
 
b
 
, RANTES),
petri dishes were coated for 2 h at room temperature with neutral-
izing antibodies in PBS, at concentrations (10–30 
 
m
 
g/ml) expected
to neutralize the amounts of cytokines found in culture superna-
tants. Control plates were coated with normal goat IgG (55 
 
m
 
g/ml).
LPS-conditioned supernatants were incubated in the sensitized
dishes overnight at 37
 
8
 
C, then collected and used immediately.
 
HIV-1 Detection.
 
HIV-1 p24 Ag concentrations in the cul-
ture supernatants were determined by ELISA (17). In brief, p24
Ag from a detergent lysate of virions was captured by an immobi-
lized anti-p24 Ag polyclonal antibody (D7320; Aalto Bio Re-
agents, Dublin, Ireland). Bound p24 Ag was then detected using
an alkaline phosphatase–conjugated anti-p24 Ag monoclonal an-
tibody (BC 1071-AP; Aalto Bio Reagents) and the AMPAK
ELISA amplification system (DAKO A/S, Glostrup, Denmark).
RT activity in the supernatants of HIV-infected MDM was as-
sayed as described in reference 18. In brief, 10 
 
m
 
l of cell-free culture
supernatants were added to 50 
 
m
 
l of a mixture containing poly(A),
oligo (dT) (Pharmacia), MgCl
 
2
 
, and 
 
32
 
P-labeled deoxythymidine
5
 
9
 
-triphosphate (dTTP) (Amersham) in a 96-well V-bottomed mi-
crotiter plate, and incubated 1.5 h at 37
 
8
 
C. 5 
 
m
 
l of the RT reaction
mixture were then dotted onto DE81 paper (Whatman, Maidstone,
England), dried, washed, and subsequently counted on a micro-
plate scintillation counter (Packard Instrument Co., Meriden, CT).
 
Immunofluorescence.
 
Expression of CD14 was detected by di-
rect immunofluorescence, as previously described (19). Cultured
monocytes and/or MDM in staining buffer (RPMI-1640, 10%
AB
 
1
 
 serum, containing 0.01% sodium azide) were incubated with
fluorochrome-conjugated P9 mAb or isotype control for 40 min
at 4
 
8
 
C. The cells were then extensively washed and fixed in 2%
paraformaldehyde. Percentages of positive cells and mean fluores-
cence intensity (MFI) were analyzed by a FACScan
 
Ò
 
 (Becton Dick-
inson) gating on the monocyte population, as defined by forward
and side light scatter.
 
Competitive PCR Amplification.
 
This procedure was described
in detail elsewhere (20). In brief, total RNA was extracted ac-
cording to the guanidine thiocyanate procedure (21), and treated
with RNase-free DNase I (Boehringer, Mannheim, Germany) to
remove traces of contaminating DNA. First-strand cDNA synthesis
was obtained by priming with random hexamers and reverse tran-
scription in 20 
 
m
 
l of RT mix containing 75 mM KCl, 50 mM
Tris–HCl (pH 8.3), 3 mM MgCl
 
2
 
, 0.4 mM each dNTP (Pharmacia),
400 U Moloney murine leukemia virus (MMLV)–RT (Promega,
Madison, WI), 20 U RNasin (Promega). RNA was preheated at
65
 
8
 
C for 5 min and incubated with the reaction mix at 37
 
8
 
C. Af-
ter 1 h, the reaction was stopped by incubation at 95
 
8
 
C for 5 min
and samples were cooled on ice. Amplification of CC–CKR-5
cDNA was performed using primers CKR-9 (5
 
9
 
-CATCAT-
CCTCCTGACAATCG) and CKR-10 (5
 
9
 
-ATGGTGAAGATA-
AGCCTCACAG). Quantification of CC–CKR-5 mRNA levels
in MDM was carried out by a competitive PCR procedure using
a competitor DNA fragment carrying the primer recognition sites
for 
 
b
 
-actin (BA1 and BA4 [22]) and for CKR-5 (primers CKR-9
and CKR-10). 
 
b
 
-actin is used as a standard to monitor the effi-
ciency of total DNA extraction. A schematic representation of
this competitor is shown in Fig. 6 
 
A
 
 and its construction is de-
scribed in the legend to Fig. 6. 
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Competitive PCR amplifications were carried out by adding
to the sample increasing concentrations of the competitive tem-
plates, in 100 
 
m
 
l of PCR buffer (50 mM KCl, 10 mM Tris–HCl,
2 mM MgCl
 
2
 
) containing the two primers (100 pmol each), the
four dNTPs (200 
 
m
 
M each), and 2.5 U of 
 
Taq
 
 DNA polymerase
(Perkin Elmer, Emeryville, CA). Samples were submitted to 50
cycles of amplification with the following cycle profiles: denatur-
ation at 95
 
8
 
C for 30 s, annealing at 60
 
8
 
C (primer sets CC–CKR-5
and 
 
b
 
-actin) for 30 s, extension at 72
 
8
 
C for 30 s. After amplifica-
tion, 10 
 
m
 
l of each PCR reaction were resolved on a 8% nonde-
naturing polyacrylamide gel, visualized under UV light after ethi-
dium bromide staining and photographed. Quantification of the
amplification products was obtained by densitometric scanning.
 
Determination of Viral DNA Load by Semiquantitative PCR.
 
High molecular weight DNA was extracted from MDM cultures
exposed to HIV-HH1
 
Ba-L
 
 for 14 h by overnight incubation at
37
 
8
 
C in lysis buffer (10 mM Tris–HCl, pH 8.3, 1 mM EDTA,
0.5% Nonidet P-40, 0.5% Tween 20, 0.3 mg/ml proteinase K)
followed by extraction with a phenol/chloroform/isoamyl alco-
hol mixture (25:24:1) and ethanol precipitation. Samples were
amplified using a sets of nested primers specific for the pol gene
(outer primer set, JA79/82; inner primer set, JA 80/81), as previ-
ously described (23). Viral DNA load was determined by progres-
sively diluting the samples, and testing each dilution in five paral-
lel reactions. As a positive control, HIV-1-infected cells were
diluted in uninfected cells so as to contain 10 and 1 HIV-1 viral
DNA copies. The number of viral DNA copies per 106 MDM
was calculated according to the Poisson distribution formula. The
sensitivity of the PCR assay was shown to be one copy of HIV-1
per 105 cells (24).
Results
LPS Suppresses HIV-1 Replication in MDM Cultures Infect-
ed in Vitro. To characterize the effects of LPS on the rep-
lication of HIV-1 in monocytic cells, MDM from normal
donors were infected in vitro with the monocytotropic
HIV-1Ba-L strain, in the presence or absence of LPS (1 mg/ml).
Fig. 1 A shows that p24 Ag secretion in untreated MDM
cultures rapidly reached high levels, which were main-
tained for over 10 d. In contrast, p24 Ag secretion by LPS-
treated MDM remained extremely low throughout the
culture time. RT activity in the same cultures showed a
similar pattern (data not shown). Fig. 1 B shows that LPS-
dependent inhibition of p24 Ag secretion was also observed
in MDM cultures infected in vitro with HIV-15088, a pri-
mary isolate from an asymptomatic HIV-1-infected patient
with the biological characteristics of an NSI isolate. LPS
had a potent inhibitory effect on the replication of both
HIV-1Ba-L and HIV-15088. Fig. 1 C shows that p24 Ag se-
cretion was inhibited by .70% using LPS at a concentra-
tion of 1 ng/ml. Notably, inhibition was still apparent
when LPS was added at 10 pg/ml, a physiologically signifi-
cant concentration (13). Interestingly, LPS addition did not
inhibit HIV-1 expression in MDM cultures infected with
the SI laboratory strain, HIV-1IIIB (Fig. 1 D). The surpris-
ingly high levels of replication of our HIV-1IIIB in MDM
are likely to result from multiple passages of the viral stock
in human primary PBMC. Addition of LPS did not result
in significant cell death, nor in apoptosis, as assessed by Try-
pan blue or propidium iodide staining (data not shown).
LPS-induced inhibition of HIV-1 replication was depen-
dent on the time of addition of LPS to the culture. Fig. 2
shows that HIV-1 expression was completely blocked when
LPS was added at the time of infection or 1 d later, but was
progressively less affected when LPS was added 2 or 3 d af-
ter infection with HIV-1. Notably, viral replication was
completely inhibited by pretreating MDM with LPS for 48 h
before infection. However, the inhibitory effect of LPS pre-
treatment was abolished if the cells were subsequently
washed before virus addition (data not shown). These data
suggest that LPS interferes with early events in HIV-1 in-
fection.
The Expression of CD14, the LPS Receptor, Is Upregulated
in LPS-treated, HIV-1-infected MDM. LPS has been shown
to upregulate the expression of its own receptor, CD14, in
whole blood (25). Therefore, we asked whether a modula-
tion of CD14 expression may contribute to the effects of
LPS on HIV-1 replication in MDM. Immunofluorescence
analysis of MDM cultures 2 d after HIV-1 infection showed
that CD14 expression was upregulated not only in uninfected,
LPS-treated MDM, but also in in vitro HIV-1-infected,
LPS-untreated cells (Fig. 3). Interestingly, LPS and HIV-1
synergized in upregulating CD14 expression. These data
suggest that the combined effects that HIV-1 infection and
LPS stimulation have on CD14 expression may amplify the
LPS-induced, CD14-mediated suppression of HIV-1 repli-
cation.
LPS-induced HIV-1 Suppression Is Not Mediated by an Ef-
fect on the Secretion of IL-6 and TNF-a. A number of cy-
Figure 1. LPS suppresses HIV-1 replication in MDM cultures infected
in vitro. MDM from healthy donors were infected with HIV-1Ba-L (A),
the primary NSI isolate HIV-15088 (B), or HIV-1IIIB (D), all at 500 pg/ml,
in the presence or absence of LPS (1 mg/ml). MDM were washed 1 d
later and further cultured, adding LPS every 3 d. Culture supernatants were
harvested daily, and tested for p24 Ag secretion by ELISA. The data are
representative of 10 (A), 3 (B), and 2 (D) separate experiments. In (C)
MDM were infected with HIV-1Ba-L or HIV-15088 in the presence of de-
creasing concentrations of LPS. p24 Ag secretion was assessed 5 d after in-
fection.808 Suppression of HIV-1 Infection by LPS-induced Chemokines
tokines have been described that regulate HIV-1 expression.
In particular, TNF-a and IL-6 enhance HIV-1 replication
in acutely infected MDM. The HIV-1–inducing effect of
TNF-a is mainly, if not exclusively, mediated by the acti-
vation of NF-kB, which activates LTR-driven viral RNA
transcription (26). IL-6 induces expression of viral proteins
and RT activity to levels comparable to those induced by
TNF-a, but unlike TNF-a, does not increase significantly
the levels of steady-state viral mRNA (27). Therefore, we
investigated whether a decrease in the production of these
HIV-1 stimulatory cytokines may underlie LPS-dependent
inhibition of HIV-1 replication in MDM. Fig. 4 shows that
LPS-induced IL-6 secretion was vigorous and comparable
in both uninfected and HIV-1–infected MDM cultures. In
contrast, infected cultures treated with LPS showed an im-
pairment in their ability to sustain TNF-a secretion over
time. However, stimulation with LPS released high and
comparable levels of TNF-a (.40 ng/ml) from uninfected
and infected cells at the initiation of the culture, before re-
moval of unbound virus. The decrease in TNF-a detected
after >2 d of culture did not result from masking by shed
soluble TNF receptors, nor from a selective upregulation of
membrane TNF-a (data not shown). Addition of rTNF-a
(10 and 100 U/ml) did not restore HIV-1 expression, as
detected by p24 Ag (data not shown). Thus, the decrease in
TNF-a was not responsible for the inhibitory effect of LPS
on HIV-1 replication. Loss of sensitivity of HIV-1-infected
MDM to TNF-a–mediated upregulation of HIV expres-
sion, rather than decreased levels of TNF-a, may be in-
volved in LPS-induced inhibition of HIV infection. The
mechanisms involved in TNF-a suppression are currently
under investigation.
LPS-induced Inhibition of HIV Replication Is Mediated by
Soluble Factors Active on Both MDM and T Lymphocytes.
The finding that pretreatment with LPS inhibited HIV-1
infection only if the cells were not washed before adding
the virus prompted us to investigate whether the effects of
LPS are mediated by soluble factors. To this purpose, LPS-
conditioned supernatants were obtained from MDM cul-
tures stimulated with LPS for 24 h, and LPS was neutral-
ized by the addition of polymixin B (15 mg/ml). Normal
MDM were then infected with HIV-1 and cultured either
with LPS, or with these supernatants (100% vol/vol) in the
absence of LPS. Table 1 shows that the supernatants from
LPS-treated MDM inhibited HIV-1 replication as actively
as LPS itself, even in the presence of polymixin B. Interest-
ingly, the effect of the soluble inhibitory factor(s) was not
Figure 2. LPS-induced inhibition of HIV-1 expression in MDM cul-
tures is dependent on the time of addition of LPS. MDM were infected
with HIV-1Ba-L (500 pg/ml), and stimulated with LPS (1 mg/ml) at differ-
ent times from the initiation of the culture. Culture supernatants were
harvested daily, and tested for p24 Ag secretion by ELISA. The data rep-
resent the mean of two separate experiments.
Figure 3. LPS and HIV-1 synergize in upregulating CD14 expression
in MDM. MDM were infected with HIV-1Ba-L (500 pg/ml) in the pres-
ence or absence of LPS (1 mg/ml). After 2 d of culture, CD14 expression
was assessed by direct immunofluorescence, using PE-conjugated mAb
P9 and an unrelated isotype control. The data are representative of three
separate experiments.809 Verani et al.
MDM specific. Indeed, Table 2 shows that the same LPS-
conditioned supernatants also suppressed viral expression in
T lymphocytes infected with the NSI strains HIV-1Ba-L and
HIV-1181, a primary isolate. The inhibitory effect of LPS-
conditioned MDM supernatants on HIV replication in T cells
was particularly remarkable, because LPS per se had no ef-
fect when added directly to purified infected T cells. How-
ever, LPS-conditioned supernatants failed to suppress the
replication of an SI primary isolate, HIV-15233, in T cells.
These results suggest that suppressive monokines released
by MDM upon stimulation with LPS are responsible for
the observed inhibition of HIV replication.
C–C Chemokines Released by LPS-stimulated MDM Medi-
ate the Suppression of HIV Replication. Several monokines have
been reported to suppress HIV-1 replication. Among them,
IL-10 blocks HIV replication by inhibiting the secretion of
endogenous TNF-a and IL-6 (28), cytokines that upregu-
late HIV expression. IL-1Ra, on the other hand, has been
described to be produced by HIV-infected MDM in excess
relative to IL-1a and IL-b, and thus effectively counteracts
IL-1-mediated induction of HIV expression (29). We
tested whether the release of these monokines was respon-
sible for the LPS-induced inhibition of HIV-1 expression in
MDM. To this purpose, neutralizing anti-IL-10 or anti-
IL-1Ra antibodies were added to MDM cultures infected
with HIV-1 and stimulated with LPS. Fig. 5 shows that ad-
dition of neither antibody reversed the suppression of HIV-1
replication caused by LPS, thus ruling out a role of IL-10
and IL-1Ra in HIV-1 suppression.
CD81 T lymphocytes release soluble factors that inhibit
HIV-1 replication in CD41 T cells in a manner not re-
stricted by the major histocompatibility complex (30). HIV-1
inhibition was recently shown to depend on the presence
of the C–C chemokines RANTES, MIP-1a, and MIP-1b
(31), the natural ligands of CC–CKR-5, the second recep-
Figure 4. Effects of LPS stim-
ulation and/or HIV-1 infection
on IL-6 and TNF-a secretion by
MDM. Uninfected or HIV-1Ba-L-
infected MDM were cultured in
the presence or absence of LPS
(1 mg/ml). LPS was added to the
cultures every 3 d. IL-6 and
TNF-a concentrations in the su-
pernatants were measured by
ELISA. The data are representa-
tive of four separate experiments.
Table 1. LPS-induced Inhibition of HIV Replication in MDM
Is Mediated by the Release of Soluble Factors
Culture
Supernatant
added Polymixin
HIV-1 p24 Ag
release
Day 4 Day 7
pg/ml
MDM1HIV-1 Nil 2 3,209 12,616
MDM1HIV-1 Nil 1 3,620 13,917
MDM1HIV-11
1LPS Nil 2 108 992
MDM1HIV-11
1LPS Nil 1 2,953 12,408
MDM1HIV-1 Untreated MØ 1 3,048 13,726
MDM1HIV-1 LPS-treated MØ 1 100 300
MDM from healthy donors were infected in vitro with HIV-1, in the
presence of LPS (1 mg/m), LPS-conditioned supernatants (100% vol/
vol), or polymixin B sulfate (15 mg/ml). Supernatants from infected
cultures were harvested at different timepoints, and assayed by ELISA
for p24 Ag secretion.810 Suppression of HIV-1 Infection by LPS-induced Chemokines
tor for primary NSI strains (32, 33, 34). Therefore, in pre-
liminary experiments, we assessed whether CC–CKR-5 is
expressed in MDM, and whether stimulation with LPS in-
duces the release of these chemokines. Competitive PCR
experiments were carried out to quantitatively determine
the levels of CC–CKR-5 mRNA in total cDNA isolated
from MDM. Quantification was achieved by using a DNA
fragment that acts as a dual competitor for PCR amplifica-
tion of both b-actin (as an internal standard) and CC–
CKR-5 cDNA (Fig. 6 A). Fig. 6 B shows that high levels
of CC–CKR-5 mRNA were expressed by MDM at the
time of infection. Stimulation with LPS did not upregulate
the expression of CC–CKR-5 in infected MDM (data not
shown).
Next, we investigated whether stimulation with LPS in-
duces MDM to release C-C chemokines. Table 3 shows
that addition of LPS resulted in vigorous production of
these C–C chemokines by MDM, both uninfected and in-
fected in vitro with HIV. Then, we investigated whether
the C–C chemokines released in LPS-conditioned super-
natants played a role in the inhibition of HIV-1 replication.
The simultaneous neutralization of RANTES, MIP-1a,
and MIP-1b has been shown to be required to abrogate the
HIV suppressive effects of CD81 T cell supernatants. Thus,
high concentrations of antibodies are necessary to achieve
neutralization (31). Because monocytes and MDM express
all types of Fcg receptors (CD64, CD32, and CD16), the
engagement of which is known to modulate HIV expres-
sion (35), supernatants from LPS-stimulated MDM cultures
were simultaneously depleted of RANTES, MIP-1a, and
MIP-1b by adsorption on specific antibodies immobilized
on plastic. After polymixin B was added to neutralize LPS,
the chemokine-depleted supernatants were added to HIV-
1-infected MDM from different donors. In the representa-
tive experiment shown in Table 4, LPS-conditioned super-
natants completely inhibited p24 Ag secretion. Depletion
of C–C chemokines neutralized the inhibitory activity of
the supernatants. In contrast, supernatants adsorbed on
control goat IgG were almost as inhibitory as the unde-
pleted ones. Our data suggest that the LPS-dependent re-
lease of HIV-1 suppressive chemokines plays a major role
in the inhibition of HIV-1 replication in MDM.
Table 2. Soluble Factors Released by LPS-treated MDM Inhibit the Replication of NSI HIV-1 Strains in T Lymphocytes
Culture Supernatant added Polymixin
HIV-1 p24 Ag release
Ba-L 181 5233
pg/ml
T cells1HIV-1 22 2,155 8,755 7,057
T cells1HIV-1 21 2,355 6,390 7,592
T cells1HIV-11LPS 22 2,344 7,795 6,793
T cells1HIV-11LPS 21 2,086 7,885 7,738
T cells1HIV-1 Untreated MØ 1 2,225 8,927 7,462
T cells1HIV-1 LPS-treated MØ 1 47 281 7,198
Lymphocytes from healthy donors were infected in vitro with two NSI HIV-1 strains, HIV-1Ba-L and HIV-1181, or with an SI strain, HIV-15233, in
the presence or absence of LPS (1 mg/m), LPS-conditioned supernatants (100% vol/vol) or polymixin B, sulfate (15 mg/ml). Supernatants from in-
fected cultures were harvested 5 d after infection, and assayed by ELISA for p24 Ag secretion.
Figure 5. Effects of neutralizing antibodies against HIV-1-inhibitory
cytokines. MDM were infected with HIV-1Ba-L and stimulated with LPS
(1 mg/ml), in presence or absence of neutralizing anti-IL-1Ra or anti-IL-10
antibodies (10 mg/ml). Culture supernatants were harvested daily, and
tested for p24 Ag secretion by ELISA. The data represent the mean of
two separate experiments. Control antibodies had no effect on p24 Ag se-
cretion.811 Verani et al.
Competitive inhibition of HIV-1 coreceptor utilization
by released chemokines is expected to result in the inhibi-
tion of HIV entry into MDM (32–34). Therefore, we
tested the effects of LPS and LPS-conditioned supernatants
on the early stages of the HIV-1 replication cycle by assess-
ing the levels of proviral DNA in MDM incubated with
HIV-1Ba-L for 14 h, in the presence or absence of LPS and
LPS-conditioned supernatants. Viral DNA load was deter-
mined by a semiquantitative nested PCR procedure, using
two primer sets specific for the pol gene (23, 24). In a rep-
resentative experiment, 5,860 viral DNA copies were de-
tected in 106 infected MDM 14 h after infection. Addition
of LPS or LPS-conditioned supernatants reduced the num-
ber of viral DNA copies to 407 and 585 per 106 MDM, re-
spectively, thus decreasing viral load by 93 and 90%. The
finding that LPS treatment suppressed the rate of proviral
DNA formation at an early time after MDM infection is
consistent with the reported ability of C–C chemokines to
interfere with HIV-1 entry.
Recombinant C–C Chemokines Inhibit HIV-1 Replication in
Human MDM. To assess whether C–C chemokines are
sufficient to inhibit HIV-1 replication in MDM, recombi-
nant RANTES, MIP-1a, and MIP-1b were added to HIV-
infected MDM, alone or in combination. Fig. 7 (left) shows
that a combination of the three chemokines, each at a con-
centration of 50 ng/ml, inhibited the replication of HIV-1Ba-L
in infected MDM by 76%. In the same experiments, addi-
tion of LPS reduced p24 Ag release by 75%. Among the
three chemokines, RANTES was the most effective one,
because it inhibited HIV-1Ba-L infection as efficiently as
LPS when used at a concentration of 250 ng/ml. Notably,
the inhibitory effect of C–C chemokines on HIV-1 repli-
cation was even more pronounced in MDM cultures in-
fected with NSI primary viral isolates. Indeed, Fig. 7 (right)
shows that RANTES, MIP-1a, and MIP-1b blocked the
replication of HIV-15088 by .75% even when used indi-
vidually at a concentration as low as 10 ng/ml. The combi-
nation of the three chemokines suppressed HIV-15088 by
over 90%. The concentrations of recombinant chemokines
used in our experiments were physiologically significant.
Indeed, the assessment of the concentrations of endogenous
chemokines released by MDM during the overnight incu-
bation with virus and LPS before washing (data not shown)
demonstrated that at the time of in vitro infection, HIV is
exposed to similar amounts of chemokines. These results
show that recombinant chemokines are sufficient to inhibit
HIV infection in human MDM.
Discussion
For several years, it has been known that stimulation
with bacterial LPS protects macrophages from productive
infection by HIV-1 in vitro (15, 16). Despite the potential
implications of this finding for the pathogenesis and treat-
ment of HIV infection, the mechanisms responsible for the
HIV suppressive effect of LPS have remained unknown.
Our present results indicate that LPS stimulates human MDM
to release soluble factors, the C–C chemokines RANTES,
MIP-1a, and MIP-1b, that strongly inhibit HIV replica-
tion, not only in macrophages but also in T lymphocytes.
These data may help redefine our current understanding
of the role played by monocyte/macrophages in the patho-
genesis of HIV infection. Macrophages have been viewed
mostly negatively, as major targets for infection (3, 4), res-
ervoirs for the virus (1, 2), triggers for T cell apoptosis (36,
37), and last but not least, as a source of soluble factors
Figure 6. MDM express CC–CKR-5 mRNA. Total RNA was ex-
tracted from untreated MDM. RNA samples were treated with DNase I
to remove traces of contaminating DNA and reverse transcribed using
random hexameric primers. The cDNA products were mixed to scalar
amounts of a synthetic competitor DNA fragment containing primer rec-
ognition sites for both b-actin and CC–CKR-5 amplification, and ampli-
fied with the respective primer pairs. (A) Schematic representation of the
competitor DNA fragment used for the quantification of CC–CKR-5
and b-actin cDNA. The fragment contains a core sequence derived from
the human b-actin cDNA, carrying a 20-bp insertion in the middle (closed
box). Amplification with the b-actin-specific primer set BA1–BA4 detects
a 226-bp product on human cDNA, and a 246-bp product from the
competitor DNA. To this core sequence, the primer recognition sites for
human CC–CKR-5 amplification were added at the two ends (indicated
by gray boxes) by reamplification with composite primers corresponding
to the CKR-91BA1 sequence at one end and CKR-101BA4 at the
other end. Amplification with CKR-9 and CKR-10 generates a 288-bp
fragment from the competitor template and a 368-bp fragment from the
CC–CKR-5 cDNA. (B) Competitive PCR for the quantification of CC–
CKR-5 and b-actin mRNAs. cDNA samples from untreated MDM
were mixed with tenfold dilution of the competitor DNA fragment as in-
dicated, and amplified with primer sets CKR-9/CKR-10 and BA1/BA4
for CC–CKR-5 and b-actin mRNA quantification. Amplification prod-
ucts were resolved by polyacrylamide gel electrophoresis, stained with
ethidium bromide, and quantified by densitometric scanning. According
to the principles of competitive PCR, quantification of the target mole-
cules in the samples was obtained by estimation of the ratio between the
amplification products, as reported at the bottom of each gel. Furthermore,
since the same competitor DNA fragment acts as a competitor for quantifica-
tion of both CC–CKR-5 and b-actin, standardization for mRNA input is
obtained by estimating the ratio between the two measurements, as indi-
cated at the bottom of the figure. M, molecular weight markers.812 Suppression of HIV-1 Infection by LPS-induced Chemokines
(TNF-a, IL-1, IL-6) that sustain viral replication (27, 38,
39). The potential for a defensive role of macrophages only
became clear after C–C chemokines have been shown to
exert a potent inhibitory effect on HIV replication (31). These
chemoattractants are vigorously secreted not only by CD81
T lymphocytes, the cells traditionally implicated in HIV-1
suppression, but also by activated monocyte/macrophages
(40). Important indications about the possible mechanism
of action of these HIV-suppressive chemokines have emerged
from a series of recent reports, which demonstrated that se-
lected chemokine receptors act as critical surface membrane
cofactors for HIV infection (32–34, 41–43). These include
CC–CKR-5, a RANTES, MIP-1a, and MIP-1b receptor
that is used by most primary NSI strains, and LESTR/fusin,
the receptor for the lymphocyte chemoattractant SDF-1
(44, 45), used by cell line–adapted SI strains, as well as CC–
CKR-2b and CC–CKR-3, which may also be used by a
limited number of isolates. C–C chemokines block mem-
brane fusion and HIV-1 entry, either by competing for the
HIV-1 binding site on CC–CKR-5, and/or through the
downregulation of surface receptor expression (32, 33, 34).
Within this context, our data suggest that a receptor for
RANTES, MIP-1a, and MIP-1b is a major cofactor for
HIV-1 entry in macrophages, as well as T cells. This hy-
Table 3. C–C Chemokine Secretion in MDM Cultures
Day 2 Day 5
MIP-1a MIP-1b RANTES MIP-1a MIP-1b RANTES
pg/ml pg/ml
Experiment 1
Nil 1,710 591 198 900 610 190
LPS 39,297 17,164 12,740 2,014 2,302 2,494
HIV 2,040 627 281 1,227 1,612 542
HIP1LPS 34,452 20,253 8,380 2,266 3,719 818
Experiment 2
Nil 380 50 38 1,200 1,300 67
LPS 22,680 37,590 12,080 25,480 47,220 2,279
HIV 1,750 2,330 47 2,960 8,200 75
HIV1LPS 21,710 20,110 8,890 7,440 13,960 332
Uninfected or HIV-1Ba-L-infected MDM were cultured in the presence or absence of LPS (1 mg/ml). LPS was added to the cultures every 3 d. Su-
pernatants were harvested after 2 and 5 d of culture. The concentrations of C–C chemokines in the supernatants were measured by ELISA.
Table 4. Antibody-mediated Depletion of C–C Chemokines Neutralizes the HIV Suppressive Activity of LPS-conditioned Supernatants
Culture Supernatant added Polymixin Depletion HIV-1 p24 Ag
pg/ml
MDM1HIV-1 22 24,516
MDM1HIV-1 21 24,426
MDM1HIV-11LPS 22 2 597
MDM1HIV-11LPS 21 24,500
MDM1HIV-1 Untreated MØ 125,739
MDM1HIV-1 LPS-treated MØ 12 176
MDM1HIV-1 LPS-treated MØ 1 Anti-chemokines 3,597
MDM1HIV-1 LPS-treated MØ 1 Normal goat IgG 806
MDM from healthy donors were infected in vitro with HIV-1Ba-L, in the presence of LPS-conditioned supernatants (100% vol/vol), undepleted or
depleted of monokines by adsorption on specific neutralizing antibodies or control IgG immobilized on plastic. Polymixin B sulfate was added at a
concentration of 15 mg/ml. Supernatants from infected cultures were harvested after 4 d of culture, and assayed by ELISA for p24 Ag secretion. The
table shows the results of a representative experiment.813 Verani et al.
pothesis is supported by a number of findings presented in
this paper: (a) at the time of infection, MDM expressed
mRNA for CC–CKR-5, the b-chemokine receptor; (b)
stimulation with LPS induced the release of endogenous
C–C chemokines, and reduced viral DNA load in infected
MDM by .90% as early as 14 h after infection; (c) deple-
tion of C–C chemokines strongly reduced the HIV-sup-
pressive capacity of LPS-conditioned MDM supernatants; (d)
recombinant chemokines at physiologically significant con-
centrations inhibited the replication of HIV-1 NSI strains in
MDM, and (e) activation of MDM with LPS inhibited the
replication of NSI primary isolates, but not of HIV-1IIIB, an
SI laboratory strain. This pattern is consistent with the ob-
servation that C–C chemokines do not block the replica-
tion of HIV-1IIIB (31), because this SI strain, unlike HIV-1Ba-L
and the NSI strains, requires LESTR/fusin, rather than
CC–CKR-5, as a coreceptor for entry and fusion (41).
The suppressive effect of C–C chemokines on MDM in-
fection by NSI HIV-1 strains is supported by the observa-
tion that recombinant RANTES, MIP-1a, and MIP-1b
potently inhibited fusion between primary macrophages
and HIV-1Ba-L Env-expressing cells (34). Furthermore, it
has been recently shown that both macrophages and CD41
T cells from multiply exposed uninfected individuals (46)
resist infection by primary NSI isolates of HIV-1, while re-
maining susceptible to infection by SI strains (47). It is not
yet clear whether resistance results from a defect in second
receptor usage secondary to C–C chemokine hyperpro-
duction (46) and/or from mutations in the CC–CKR-5
gene that generate a nonfunctional receptor unable to sup-
port cell fusion and infection by NSI HIV-1 strains (48).
However, it seems likely that susceptibility to HIV-1 infec-
tion of both macrophages and T cells is genetically deter-
mined, and critically regulated by the interactions between
C–C chemokines and their receptors.
The issue of C–C chemokine-induced inhibition of
HIV-1 replication in macrophages is still somewhat contro-
versial. Dragic et al. (33) recently reported that entry of
NSI HIV-1 strains into primary macrophages was relatively
insensitive to C–C chemokines. This discrepancy with our
results is likely to be caused by differences in the experi-
mental conditions. The readout in our experiments was p24
Ag secretion in MDM cultures infected with several HIV-1
strains, including primary isolates from HIV-1-infected pa-
tients. In contrast, Dragic et al. assessed virus entry by a sin-
gle-cycle infection with an env-deficient virus, which also
carries the luciferase reporter gene, complemented by en-
velope glycoprotein expressed in trans (33). This assay, al-
though elegant, is necessarily artificial, and may not capture
the full complexity of virus–host cell interactions in mac-
rophages infected with naturally occurring HIV-1 strains.
On the other hand, a number of differences in culture con-
ditions (i.e., MDM propagation and stimulation and/or vi-
rus source and/or activity of recombinant chemokines) may
have determined the lack of HIV suppression observed by
Schmidtmayerova et al. (49). In our hands, different batches
of recombinant C–C chemokines have reproducibly sup-
pressed infection by different HIV-1 NSI strains over sev-
eral months.
While the results obtained with recombinant chemo-
kines clearly show that these chemoattractants are sufficient
to suppress HIV replication in MDM, it is possible that
LPS-conditioned supernatants contain additional factor(s)
with HIV suppressive effects. Preliminary experiments in
our laboratory indicate that the replication of some HIV-1
strains is insensitive to C–C chemokine-mediated inhibi-
tion, but is blocked by LPS-conditioned supernatants (Ve-
rani, A., G. Scarlatti, and D. Vercelli, manuscript in prepa-
ration). The nature of other potential HIV-suppressive
factor(s) contained in the LPS-conditioned MDM superna-
tants, and their function vis-a-vis chemokines, is currently
under investigation. IFN (a and/or b) is a good candidate,
because it is known to be released by LPS-stimulated
MDM (50), and to block HIV replication (51).
Finally, the observation that LPS-stimulated macrophages
release soluble factors that effectively inhibit HIV replica-
Figure 7. Recombinant C–C
chemokines inhibit HIV-1 repli-
cation in human MDM. MDM
from healthy donors were in-
fected in vitro with HIV-1Ba-L
(left) or with the NSI primary vi-
ral isolate HIV-15088 ( right), in
the presence or absence of LPS
(1  mg/ml) and recombinant
chemokines. Chemokines were
added to HIV-1Ba-L-infected cul-
tures at a concentration of 250
ng/ml when used individually,
and 50 ng/ml each when used
in combination. For HIV-15088-
infected cultures, chemokines
were used at 10 ng/ml, individu-
ally and in combination. Super-
natants from infected cultures
were harvested at different time-
points, and assayed by ELISA for
p24 Ag secretion.814 Suppression of HIV-1 Infection by LPS-induced Chemokines
tion in both macrophages and T cells may prompt a rein-
terpretation of the role played by bacterial superinfections
in the pathogenesis and progression of HIV infection. It has
been recently shown that CD14 is not just the receptor for
LPS of gram-negative bacteria (9) but is a multipurpose
receptor for foreign lipoglycans of gram-positive bacteria
and mycobacteria (52, 53). Thus, a vast array of exogenous
stimuli derived from microbial pathogens may conceivably
trigger intense chemokine release. In this perspective, the
effect of bacterial superinfections in patients with HIV-1
immunodeficiency may be complex and somewhat coun-
terintuitive. The chemokine response triggered by the in-
fectious agent upon interaction with the macrophages of
the host in fact may contribute to the containment of HIV-1
infection in the main targets of the virus, T cells, and
mononuclear phagocytes.
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